Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992183 · ClinicalTrials.gov registry record
Utility of CAML as Diagnostic for Early Stage Lung Cancer
A clinical trial, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- 200
- Enrollment target
NCT03992183: Clinical Trial study, sponsored by Fox Chase Cancer Center.
NCT03992183 is a clinical trial that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03992183 was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- 200 participants
- Enrollment target
Study Summary
Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules. Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy. Model combinations of clinical factors with the presence/absence of CAMLS to refine strategies for assessment of patients with pulmonary nodules. Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number
Primary Outcome
Laboratory studies performed on blood drawn at Creatv Microtech will determine the prevalence of CAMLS in pulmonary nodules.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2022-11-14 |
Why NCT03992183 stopped before completion
NCT03992183 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03992183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03992183 about?
NCT03992183 is a clinical study titled "Utility of CAML as Diagnostic for Early Stage Lung Cancer". Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules. Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy. Model combinations of clinical factors with the presence/absence of CAML...
What is the current status of trial NCT03992183?
This trial is currently terminated. The enrollment target is 200 participants. The study started on 2019-05-21. Estimated completion is 2022-11-14.
Who is sponsoring clinical trial NCT03992183?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI